Patents by Inventor Neelu Kaila

Neelu Kaila has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HPK1 antagonists and uses thereof
    Patent number: 11926625
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Grant
    Filed: March 4, 2022
    Date of Patent: March 12, 2024
    Assignee: Nimbus Saturn, Inc.
    Inventors: Neelu Kaila, Ian Linney, Stuart Ward, Grant Wishart, Benjamin Whittaker, William Sinko, Shawn Watts, Mark Anthony Ashwell, Byron Scott Delabarre
  • HPK1 ANTAGONISTS AND USES THEREOF
    Publication number: 20240025898
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Application
    Filed: July 11, 2023
    Publication date: January 25, 2024
    Inventors: Neelu KAILA, Ian LINNEY, Stuart WARD, Grant WISHART, Ben WHITTAKER, Alexandre COTE, Jeremy Robert GREENWOOD, Abba LEFFLER, Steven K. ALBANESE, Daniel L. SEVERANCE
  • HPK1 ANTAGONISTS AND USES THEREOF
    Publication number: 20230117631
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Application
    Filed: March 4, 2022
    Publication date: April 20, 2023
    Inventors: Neelu KAILA, Ian Linney, Stuart Ward, Grant Wishart, Benjamin Whittaker, William Sinko, Shawn Watts, Mark Anthony Ashwell, Byron Scott Delabarre
  • HPK1 ANTAGONISTS AND USES THEREOF
    Publication number: 20230096641
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Application
    Filed: February 11, 2022
    Publication date: March 30, 2023
    Inventors: Neelu KAILA, Ian LINNEY, Stuart WARD, Grant WISHART, Benjamin WHITTAKER, William SINKO, Shawn WATTS, Mark Anthony ASHWELL, Byron Scott DELABARRE
  • CTPS1 INHIBITORS AND USES THEREOF
    Publication number: 20230077316
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of CPTS1, and the treatment of CPTS1-mediated disorders.
    Type: Application
    Filed: October 22, 2021
    Publication date: March 9, 2023
    Inventors: Kevin D. KREUTTER, Lewis Whitehead, Angela V. West, Steven K. Albanese, Andreas Verras, Shaughnessy Robinson, Neelu Kaila, Sebastien Campos, Kevin Demarco
  • HPK1 antagonists and uses thereof
    Patent number: 11548890
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Grant
    Filed: July 12, 2021
    Date of Patent: January 10, 2023
    Assignee: Nimbus Saturn, Inc.
    Inventors: Neelu Kaila, Ian Linney, Stuart Ward, Grant Wishart, Ben Whittaker, Alexandre Cote, Jeremy Robert Greenwood, Abba Leffler, Steven K. Albanese, Daniel L. Severance
  • HPK1 ANTAGONISTS AND USES THEREOF
    Publication number: 20220363695
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Application
    Filed: March 29, 2022
    Publication date: November 17, 2022
    Inventors: Neelu KAILA, Ian LINNEY, Stuart WARD, Grant WISHART, Benjamin WHITTAKER, Alexandre COTE, Jeremy Robert GREENWOOD, Abba LEFFLER
  • Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrol[3,4-c]pyridin-1-ones as HPK1 antagonists
    Patent number: 11078201
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: August 3, 2021
    Assignee: Nimbus Saturn, Inc.
    Inventors: Neelu Kaila, Ian Linney, Stuart Ward, Grant Wishart, Ben Whittaker, Alexandre Cote, Jeremy Robert Greenwood, Abba Leffler, Steven K. Albanese, Daniel L. Severance
  • Substituted isoindolin-1-ones and 2,3-dihydro-1H-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists
    Patent number: 11034694
    Abstract: The present invention provides compounds of formula I: or pharmaceutically acceptable salts and/or pharmaceutical compositions thereof. The present invention also provides methods for the inhibition of HPK1 and methods for the treatment of HPK1-mediated disorders.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: June 15, 2021
    Assignee: Nimbus Saturn, Inc.
    Inventors: Neelu Kaila, Ian Linney, Stuart Ward, Grant Wishart, Ben Whittaker, Alexandre Cote, Jeremy Robert Greenwood, Abba Leffler, Steven K. Albanese, Daniel L. Severance
  • Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as hpk1 antagonists
    Patent number: 11028085
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: June 8, 2021
    Assignee: Nimbus Saturn, Inc.
    Inventors: Neelu Kaila, Ian Linney, Stuart Ward, Grant Wishart, Ben Whittaker, Alexandre Cote, Jeremy Robert Greenwood, Abba Leffler, Steven K. Albanese, Daniel L. Severance
  • Substituted isoindolin-1-ones and 2,3-dihydro-1h-pyrrolo[3,4-c]pyridin-1-ones as HPK1 antagonists
    Patent number: 11021481
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: June 1, 2021
    Assignee: Nimbus Saturn, Inc.
    Inventors: Neelu Kaila, Ian Linney, Stuart Ward, Grant Wishart, Ben Whittaker, Alexandre Cote, Jeremy Robert Greenwood, Abba Leffler, Steven K. Albanese, Daniel L. Severance
  • Pyrrolo[2,3-d]pyrimidine derivatives
    Patent number: 10966980
    Abstract: Described herein are pyrrolo{2,3-d}pyrimidine derivatives, their use as Janus Kinase (JAK) inhibitors, pharmaceutical compositions containing them, and therapeutic uses thereof.
    Type: Grant
    Filed: August 10, 2015
    Date of Patent: April 6, 2021
    Assignee: Pfizer Inc.
    Inventors: Michael L. Vazquez, Neelu Kaila, Jamison B. Tuttle, Patrick Robert Verhoest, Matthew R. Reese, Karen J. Coffman, Tarek Samad, James M. Duerr, Simone Sciabola, Mihir D. Parikh
  • SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS
    Publication number: 20210087190
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Application
    Filed: September 14, 2020
    Publication date: March 25, 2021
    Inventors: Neelu KAILA, Ian LINNEY, Stuart WARD, Grant WISHART, Ben WHITTAKER, Alexandre COTE, Jeremy Robert GREENWOOD, Abba LEFFLER
  • SUBSTITUTED ISINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,3-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS
    Publication number: 20210087189
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Application
    Filed: September 14, 2020
    Publication date: March 25, 2021
    Inventors: Neelu KAILA, Ian LINNEY, Stuart WARD, Grant WISHART, Ben WHITTAKER, Alexandre COTE, Jeremy Robert GREENWOOD, Abba LEFFLER
  • HPK1 ANTAGONISTS AND USES THEREOF
    Publication number: 20210078996
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Application
    Filed: September 11, 2020
    Publication date: March 18, 2021
    Inventors: Neelu KAILA, Ian LINNEY, Stuart WARD, Grant WISHART, Ben WHITTAKER, Alexandre COTE, Jeremy Robert GREENWOOD, Abba LEFFLER, Steven K. ALBANESE, Daniel L. SEVERANCE
  • SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROL[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS
    Publication number: 20210078997
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Application
    Filed: September 14, 2020
    Publication date: March 18, 2021
    Inventors: Neelu KAILA, Ian LINNEY, Stuart WARD, Grant WISHART, Ben WHITTAKER, Alexandre COTE, Jeremy Robert GREENWOOD, Abba LEFFLER, Steven K. ALBANESE, Daniel L. SEVERANCE
  • SUBSTITUTED ISOINDOLIN-1-ONES AND 2,3-DIHYDRO-1H-PYRROLO[3,4-c]PYRIDIN-1-ONES AS HPK1 ANTAGONISTS
    Publication number: 20210078998
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of HPK1, and the treatment of HPK1-mediated disorders.
    Type: Application
    Filed: September 14, 2020
    Publication date: March 18, 2021
    Inventors: Neelu KAILA, Ian LINNEY, Stuart WARD, Grant WISHART, Ben WHITTAKER, Alexandre COTE, Jeremy Robert GREENWOOD, Abba LEFFLER, Steven K. ALBANESE, Daniel L. SEVERANCE
  • RORC2 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20200039960
    Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.
    Type: Application
    Filed: October 18, 2019
    Publication date: February 6, 2020
    Applicant: Pfizer Inc.
    Inventors: Mark Edward Schnute, Göran Mattias Wennerstål, James Robert Blinn, Neelu Kaila, James Richard Kiefer, Jr., Scot Richard Mente, Ravi G. Kurumbail, Marvin Jay Meyers, Atli Thorarensen, Li Xing, Christoph Wolfgang Zapf, Edouard Zamaratski, Andrew Christopher Flick, Peter Jones
  • Methyl- and Trifluromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof
    Publication number: 20190387710
    Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
    Type: Application
    Filed: September 6, 2019
    Publication date: December 26, 2019
    Applicant: Pfizer Inc.
    Inventors: Mark Edward Schnute, Andrew Christopher Flick, Peter Jones, Neelu Kaila, Scot Richard Mente, John David Trzupek, Michael L. Vazquez, Goran Mattias Wennerstal, Li Xing, Edouard Zamaratski, Liying Zhang, Rayomand Jal Unwalla
  • Methyl- and trifluromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof
    Patent number: 10426135
    Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
    Type: Grant
    Filed: February 6, 2019
    Date of Patent: October 1, 2019
    Assignee: Pfizer Inc.
    Inventors: Mark Edward Schnute, Andrew Christopher Flick, Peter Jones, Neelu Kaila, Scot Richard Mente, John David Trzupek, Michael L. Vazquez, Goran Mattias Wennerstal, Li Xing, Edouard Zamaratski, Liying Zhang, Rayomand Jal Unwalla